Harmony Biosciences Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HRMY research report →
Companywww.harmonybiosciences.com
Harmony Biosciences Holdings, Inc. , a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
- CEO
- Jeffrey Dayno
- IPO
- 2020
- Employees
- 268
- HQ
- Plymouth Meeting, PA, US
Price Chart
Valuation
- Market Cap
- $1.82B
- P/E
- 12.46
- P/S
- 2.02
- P/B
- 1.99
- EV/EBITDA
- 6.14
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 76.55%
- Op Margin
- 21.08%
- Net Margin
- 16.20%
- ROE
- 17.19%
- ROIC
- 12.50%
Growth & Income
- Revenue
- $868.45M · 21.51%
- Net Income
- $158.69M · 9.07%
- EPS
- $2.76 · 7.81%
- Op Income
- $208.47M
- FCF YoY
- 59.09%
Performance & Tape
- 52W High
- $40.87
- 52W Low
- $25.52
- 50D MA
- $29.47
- 200D MA
- $32.70
- Beta
- 0.96
- Avg Volume
- 903.20K
Get TickerSpark's AI analysis on HRMY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Germano Geno J | other | 21,231 |
| May 14, 26 | Germano Geno J | other | 0 |
| May 14, 26 | Szyper Linda M | other | 21,872 |
| May 14, 26 | Philip Ron M | other | 21,872 |
| May 14, 26 | Graf R. Mark | other | 21,872 |
| May 14, 26 | Sabater Juan A. | other | 21,872 |
| May 14, 26 | Sender Gary | other | 21,872 |
| May 1, 26 | Budur Kumar | other | 18,750 |
| May 1, 26 | Budur Kumar | other | 18,750 |
| May 1, 26 | Budur Kumar | other | 8,882 |
Our HRMY Coverage
We haven't published any research on HRMY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HRMY Report →